ArticleJournal of clinical biochemistry and nutrition2026
Ginsenoside Rg2 upregulates expression of Lilrb4 and inhibits the NF-κB signaling pathway to alleviate hemorrhagic shock/reperfusion-induced intestinal injury.
Article in Journal of clinical biochemistry and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemorrhagic shock/reperfusion (HS/R) injury is associated with high global mortality, and intestinal injury plays a pivotal role in driving systemic complications. This study examined the therapeutic potential of Ginsenoside Rg2 (G-Rg2) in mitigating HS/R intestinal injury and elucidated its relationship involving leukocyte immunoglobulin-like receptor B4 (Lilrb4). Using an established rat HS/R model and hypoxia/reoxygenation (H/R) IEC-6 cells, we evaluated the effects of G-Rg2 on intestinal barrier integrity, inflammatory responses, oxidative stress, and apoptosis. The results indicated that G-Rg2 treatment significantly alleviates intestinal mucosal damage, inhibits epithelial apoptosis, and restores tight junction proteins (Occludin, ZO-1).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.